Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms

Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasmsPhase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms, Published online: 17 April 2018; doi:10.1038/s41375-018-0135-8Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms

Source: Leukemia - April 17, 2018 Category: Hematology Authors: Anna B. Halpern Megan Othus Emily M. Huebner Bart L. Scott Pamela S. Becker Mary-Elizabeth M. Percival Paul C. Hendrie Kelda M. Gardner Tara L. Chen Sarah A. Buckley Kaysey F. Orlowski Asma Anwar Frederick R. Appelbaum Harry P. Erba Elihu H. Estey Roland Source Type: research